RTP Mobile Logo
Striving for Consensus on the Management of Secondary Acute Myeloid Leukemia (Video Program)
Released May 2022

Featuring perspectives from Drs Naval Daver, Stephen Strickland, Geoffrey Uy and Eunice Wang. Published May 31, 2022. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of acute myeloid leukemia.

    LEARNING OBJECTIVES

    • Develop a greater understanding of the incidence, biology and pathophysiology of secondary acute myeloid leukemia (sAML).
    • Analyze patient-specific factors and available clinical trial data guiding the selection of induction therapy for sAML to optimize clinical and quality-of-life outcomes.
    • Recognize the FDA-approved indications for CPX-351 in patients with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be optimally integrated into nonresearch care algorithms.
    • Recall available data with venetoclax in combination with azacitidine, decitabine or low-dose cytarabine for patients with newly diagnosed AML not eligible for intensive therapy, and explore the role of venetoclax in the treatment of sAML.
    • Recognize the side effects and toxicities associated with CPX-351 for patients with sAML, and develop strategies to manage and mitigate treatment-related adverse events.
    • Appreciate published research findings and clinical investigator perspectives regarding the benefits and risks of outpatient administration of induction therapy for sAML, and evaluate the applicability of this approach in various practice settings.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 3 (audio) and 2.5 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AMLThinkTank22/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/AMLThinkTank22/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/AMLThinkTank22/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/AMLThinkTank22.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Naval Daver, MD
    Director, Leukemia Research Alliance Program
    Associate Professor
    Department of Leukemia
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Cardiff Oncology, Daiichi Sankyo Inc, Fate Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlycoMimetics Inc, Hanmi Pharmaceutical, ImmunoGen Inc, NovImmune SA, Pfizer Inc, Servier Pharmaceuticals LLC, Trillium Therapeutics Inc. Consulting Agreements: AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Arog Pharmaceuticals Inc, Astellas, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, ImmunoGen Inc, Jazz Pharmaceuticals Inc, Novartis, Pfizer Inc, Servier Pharmaceuticals LLC, Shattuck Labs, Syndax Pharmaceuticals Inc, Trillium Therapeutics Inc.

    Stephen A Strickland, MD, MSCI
    Malignant Hematology and Stem Cell Transplant Medical Director
    Clinical Director, Acute Leukemia
    Assistant Professor of Medicine
    Division of Hematology/Oncology
    Vanderbilt University Department of Medicine
    Nashville, Tennessee

    Advisory Committee: AbbVie Inc, BerGenBio ASA, Genentech, a member of the Roche Group, Kura Oncology, Syros Pharmaceuticals Inc.

    Geoffrey L Uy, MD
    Professor of Medicine
    Division of Oncology
    Washington University School of Medicine
    St Louis, Missouri

    No relevant conflicts of interest to disclose.

    Eunice S Wang, MD
    Chief, Leukemia Service
    Professor of Oncology
    Roswell Park Comprehensive Cancer Center
    Buffalo, New York

    Advisory Committee: AbbVie Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Kura Oncology, Novartis, PharmaEssentia, Stemline Therapeutics Inc; Consulting Agreements: Mana Therapeutics, Rafael Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: AbbVie Inc, Rafael Pharmaceuticals Inc; Speakers Bureau: Astellas, DAVA Oncology, Kura Oncology, Stemline Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by an educational grant from Jazz Pharmaceuticals Inc.

    Release date: May 2022
    Expiration date: May 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):